It has been demonstrated that IL-17 acts as a downstream target of miR-383; thus, miR-383 operates as an HCC inhibitor and apoptosis enhancer by targeting IL-17 (Wang et al., 2019a). Here, IL17A is linked to hepatocellular carcinoma.